Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nabriva Therapeutics PLC

www.nabriva.com

Latest From Nabriva Therapeutics PLC

Keeping Track: Ayvakit Approval, Keytruda Supplement, NME Submissions

The latest drug development news and highlights from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

New Tech Payment For Old Antibiotics: US Medicare Effort Brings Lots Of Interest

CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.

Infectious Diseases Reimbursement

Promising Shionogi Candidate Moves Ahead In Gram-Negative Pneumonia

Novel Shionogi antibiotic candidate set to move ahead following positive results in Gram-negative pneumonia, where resistance and unmet needs remain critical factors.
Infectious Diseases Clinical Trials

Keeping Track: US FDA Greenlights Two More Novel Drugs, But Smacks Down Golodirsen

The latest drug development news and highlights from our US FDA Performance Tracker.
Approvals Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Antibiotic Research Institute
  • Nabriva Therapeutics AG
  • 1641640
  • Nabriva Therapeutics Forschungs GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Ireland
  • Parent & Subsidiaries
  • Nabriva Therapeutics PLC
  • Senior Management
  • Ted Schroeder, CEO
    Gary Sender, CFO
    Francesco Maria Lavino, Chief Commercial Officer
    Jennifer Schranz, MD, CMO
    Steven Gelone, MD, Pres. & COO
  • Contact Info
  • Nabriva Therapeutics PLC
    Phone: (43) 1 649 2000
    25-28 North Wall Quay
    Dublin, 1
    Ireland
UsernamePublicRestriction

Register